Opinion

Video

Key Differences Among ALK Inhibitors

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Elizabeth Castronovo, NP

Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.

ALK Inhibitor Comparison and CNS Penetration

Key Themes:

  • Overview of currently available ALK inhibitors in the metastatic setting
  • Comparative analysis of efficacy and durability of response
  • Differences in CNS penetration among ALK inhibitors

Notable Insights:

  • Dr Lovly provided a comprehensive overview of available ALK inhibitors and their comparative efficacy

Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Gordon Crofoot, MD, PA
Dr Brian Slomovitz
4 experts are featured in this series.
2 experts in this video
2 experts in this video
4 experts are featured in this series.
Samir Shah, MD, MMM, FACR
1 expert in this video
5 experts are featured in this series
Related Content
The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com
June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Rose McNulty
Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
men's health month graphic | Image Credit: Hrida-stock.adobe.com
June 3rd 2025

Men’s Health Month 2025: Spotlight on Prostate Cancer, Lifelong Health

Brooke McCormick
Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health outcomes.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Mary Caffrey
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
The authors emphasized the need for further research into improving the diagnostic performance of both blood- and stool-based tests, particularly to enhance early lesion detection. | Image credit: SewcreamStudio - stock.adobe.com
May 31st 2025

FIT Outperforms Blood-Based cfDNA Test in Detecting Precancerous Colorectal Lesions

Rose McNulty
Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo